Annual Report 2020

MANAGEMENT DISCUSSION AND ANALYSIS 10 The United Laboratories International Holdings Limited Annual Report 2020 Intermediate Products and Bulk Medicine The Group’s intermediate products and bulk medicine recorded segment external sales of RMB1,429.7 million and RMB3,620.7 million, respectively, representing a year-on-year growth of 11.7% and 0.8% respectively. During the year, external sales volume of 6-APA increased by 18.0% as compared with last year and the sales prices are increased steadily. Overseas export grew steadily and recorded a revenue of RMB2,513.4 million, representing a year-on-year growth of 7.1%. The Group continued to occupy an advantageous position in the domestic and export market of intermediate products and bulk medicine, and made active contributions to maintain the stability of the international bulk medicine supply chain during the pandemic. Finished Products The Group’s finished products recorded sales revenue of RMB3,722.1 million, representing a year-on-year increase of 5.8%. Diabetes products continued to grow steadily. Insulin series recorded an aggregate sales revenue of RMB1,234.7 million during the year, representing a year-on-year increase of 35.7%. Among that, sales revenue of recombinant human insulin injections and insulin glargine injections amounted to RMB832.5 million and RMB402.2 million, respectively, and sales volume increased by 22.0% and 81.3%, respectively as compared with last year. In terms of other finished products, due to the limited diagnosis and treatment services of medical institutions during the pandemic in the PRC, antibiotics products recorded a sales revenue of RMB2,091.6 million during the year, representing a year-on-year decrease of 2.6%. Nervous system drugs recorded a sales revenue of RMB105.6 million during the year, representing a year-on-year increase of 34.3%. During the year, ophthalmic products recorded a sales revenue of RMB175.6 million, representing a year-on-year increase of 2.3%. Vitamin products recorded a sales revenue of RMB61.6 million, representing a year-on-year increase of 58.1%. Executive directors from left to right: Ms. Choy Siu Chit, Mr. Leung Wing Hon, Ms. Zou Xian Hong, Mr. Tsoi Hoi Shan, Ms. Zhu Su Yan and Mr. Fang Yu Ping